Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 24. pii: JCO.2014.59.4853. doi: 10.1200/JCO.2014.59.4853
    Pediatric Hodgkin Lymphoma.
    Mauz-Körholz C1,  Metzger ML2,  Kelly KM3,  Schwartz CL4,  Castellanos ME5,  Dieckmann K6,  Kluge R7,  Körholz D8
    Author information
    1Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany. christine.mauz-koerholz@uk-halle.de.
    2Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    3Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    4Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    5Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    6Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    7Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    8Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
    Abstract

    Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-term survival rates now exceeding 90% after treatment with chemotherapy alone or combined with radiotherapy (RT). Of note, global collaboration in clinical trials within cooperative pediatric HL study groups has resulted in continued progress; however, survivors of pediatric HL are at high risk of potentially life-limiting second cancers and treatment-associated cardiovascular disease. Over the last three decades, all major pediatric and several adult HL study groups have followed the paradigm of response-based treatment adaptation and toxicity sparing through the reduction or elimination of RT and tailoring of chemotherapy. High treatment efficacy is achieved using dose-dense chemotherapy. Refinement and reduction of RT have been implemented on the basis of results from collaborative group studies, such that radiation has been completely eliminated for certain subgroups of patients. Because pediatric staging and response criteria are not uniform, comparing the results of trial series among different pediatric and adult study groups remains difficult; thus, initiatives to harmonize criteria are desperately needed. A dynamic harmonization process is of utmost importance to standardize therapeutic risk stratification and response definitions as well as improve the care of children with HL in resource-restricted environments.


    © 2015 by American Society of Clinical Oncology.

    Publikations ID: 26304892
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt